Small Clinical Benefit Seen for Race-Aware Over Unaware Risk Predictions
By Elana Gotkine HealthDay Reporter
TUESDAY, Dec. 3, 2024 -- The clinical benefit of race-aware over race-unaware disease risk predictions is smaller than expected, according to a study published online Dec. 3 in the Annals of Internal Medicine.
Madison Coots, from Harvard University in Cambridge, Massachusetts, and colleagues present a decision analytic framework for considering the potential benefits of race-aware over race-unaware risk predictions. A cross-sectional study involving U.S. adults was conducted using cardiovascular disease, breast cancer, and lung cancer as case studies. Race-unaware predictions were generated via statistical marginalization, starting with risk predictions from clinically recommended race-aware models. The utility gains of the race-aware over the race-unaware models were estimated based on a simple utility function assuming constant costs of screening and constant benefit of disease detection.
The researchers found that compared with the race-aware predictions as the benchmark, the race-unaware predictions were substantially miscalibrated across racial and ethnic groups. At the population level, the clinical net benefit of race-aware over race-unaware predictions was smaller than anticipated. This result stemmed from two patterns: (1) 95 percent or more of individuals would receive the same decision across all three diseases, irrespective of whether race and ethnicity are included in the risk model; and (2) the net benefit of screening or treatment was relatively small for those who received different decisions because these patients have disease risks close to the decision threshold. Race-aware models may have a more substantial net benefit when used to inform rationing.
"Our results suggest that race-aware risk models yield smaller gains in net benefit over race-unaware models than the improvement in predictions might suggest," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-12-05 00:00
Read more
- Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study
- Abeona Therapeutics Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
- Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
- More Women Are Being Diagnosed With Breast Cancer at Later Stages
- Celiac Disease Linked to Higher Risk for Developing Alopecia Areata
- Irregular Sleep Linked to Increased Risk for Major Adverse Cardiovascular Events
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions